ENGN News
EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3
(RTTNews) - enGene Therapeutics Inc. (ENGN) released a profit for third quarter of $32.50 million...
Nasdaq News: Markets
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. As we move through the second half of 2026, our focus...
Business Wire
enGene to Participate in Upcoming Investor Conferences
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15...
Business Wire
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research...
Business Wire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (detalimogene) if...
Business Wire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
enGene Therapeutics Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates. Feedback from the urology community on the emerging...
Business Wire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026 /PRNewswire...
PR Newswire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. (enGene or the Company) (NASDAQ: ENGN) for violations of the securities laws.The investigation focuses on whether the Company issued false...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026 /PRNewswire...
PR Newswire